Immunotherapy for Infectious Diseases
Immunotherapy for Infectious Diseases
Immunotherapy for Infectious Diseases
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Index 327<br />
function, 32, 33, 182–185<br />
therapeutic targeting, 229, 230<br />
highly active antiretroviral<br />
therapy effects, see Highly<br />
active antiretroviral therapy<br />
overview, 29, 31, 154–156, 163<br />
thymic function, 186<br />
treatment, see also Highly active<br />
antiretroviral therapy,<br />
cell activation state targeting, 225,<br />
226<br />
cell entry targeting, 223–225<br />
clinical trial design<br />
challenges, 158, 159<br />
cytokine immunotherapy, 187<br />
gene therapy, see Gene therapy<br />
immune control of viral<br />
replication, 229, 230<br />
latently infected cell pool<br />
targeting, 228<br />
passive immunotherapy, see<br />
Passive immunotherapy<br />
prospects, 190<br />
range of modalities, 157<br />
structured treatment<br />
interruption, 187, 188<br />
T-cell number targeting,<br />
226–228<br />
vaccination, 188–190, 230<br />
Human papillomavirus (HPV),<br />
cervical cancer,<br />
immunogenicity, 268<br />
vaccination, 268<br />
viral protein targeting, 268, 269<br />
dendritic cell response, 102<br />
strains and diseases, 268<br />
Hybridoma, see Monoclonal antibody<br />
I<br />
IFN-α, see Interferon-α<br />
IFN-γ, see Interferon-γ<br />
IgA, see Immunoglobulin A<br />
IL-2, see Interleukin-2<br />
IL-12, see Interleukin-12<br />
Immunoglobulin, see Antibody<br />
Immunoglobulin A (IgA), mucosal<br />
immunity, 45, 46<br />
Immunosuppression, immunoglobulin<br />
therapy, 79<br />
<strong>Immunotherapy</strong>, historical perspective,<br />
3, 63<br />
Inactivated vaccine, see Vaccine<br />
Influenza virus, dendritic cell response,<br />
102<br />
Interferon-a (IFN-a), tuberculosis<br />
immunotherapy, 291<br />
Interferon-γ (IFN-γ),<br />
fungal infection management, 313<br />
tuberculosis immunotherapy, 289<br />
Interleukin-2 (IL-2),<br />
human immunodeficiency virus,<br />
immunotherapy, 187, 227–229<br />
infectivity effects, 225<br />
tuberculosis immunotherapy,<br />
285–287<br />
Interleukin-12 (IL-12),<br />
antigen-presenting cell function, 99,<br />
100<br />
fungal infection management, 315<br />
hepatitis B clearance, 254<br />
human immunodeficiency virus<br />
immunotherapy, 187<br />
tuberculosis immunotherapy, 288,<br />
289<br />
Internal image idiotype vaccine, see<br />
Vaccine<br />
Intravenous immunoglobulin (IVIG),<br />
see also Passive immunotherapy,<br />
bacterial infection management,<br />
clinical trials, 289, 290<br />
Clostridium difficile, 277<br />
Escherichia coli, 277, 278<br />
Haemophilus influenzae, 277<br />
Klebsiella, 278<br />
Neisseria, 277<br />
Pseudomonas aeruginosa, 277, 278<br />
Staphylococcus aureus, 275, 276<br />
Streptococcus, 276<br />
donors, 70<br />
fungal infection management, 313<br />
history of use, 69<br />
hyperimmune sera, 70, 72<br />
preparation, 69, 70<br />
respiratory syncytial virus therapy,<br />
251, 252<br />
safety, 70<br />
sepsis studies, 278<br />
IVIG, see Intravenous immunoglobulin<br />
J<br />
Jak, interferon signal transduction, 122
Change language